<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K3L4M3" height="0" width="0" style="display:none;visibility:hidden">

World

What the Lancet study tells us about the Oxford vaccine

9 December 2020

8:46 AM

9 December 2020

8:46 AM

While the Pfizer vaccine became the first to be used in a public vaccination programme on Tuesday, the Oxford/AstraZeneca vaccine team became the first to publish their results in a peer-reviewed journal, the Lancet.

As the press release announcing the results explained, the overall efficacy rate of the Oxford vaccine was measured at 70 per cent, but that concealed a large difference between different arms of the trial.

Already a subscriber? Log in

Easter flash sale:
10 issues for $1

Subscribe this Easter and get the next 10 issues of the magazine, plus website and app access, all for just $1.

  • Weekly delivery of the magazine
  • Unlimited access to spectator.com.au and app
  • Spectator Australia podcasts and newsletters
  • Full access to spectator.co.uk
Or

Unlock 3 articles a month

REGISTER


Comments

Easter flash sale: 10 issues for $1

Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.

Already a subscriber? Log in

Close